title: Evidence for a centrally located gate in the pore of a serotonin-gated ion channel.
abstract: Serotonin-gated ion channels (5-HT3) are members of the ligand-gated channel family, which includes channels that are opened directly by the neurotransmitter acetylcholine, GABA, glycine, or glutamate. Although there is general agreement that the second transmembrane domain (M2) lines the pore, the position of the gate in the M2 is less certain. Here, we used substituted cysteine accessibility method (SCAM) to provide new evidence for a centrally located gate that moves during channel activation. In the closed state, three cysteine substitutions, located on the extracellular side of M2, were modified by methanethiosulfonate (MTS) reagents. In contrast, 13 cysteine substitutions were modified in the open state with MTS reagents. The pattern of inhibition (every three to four substitutions) was consistent with an alpha helical structure for the middle and cytoplasmic segments of the M2 transmembrane domain. Unexpectedly, open-state modification of two amino acids in the center of M2 with three different MTS reagents prevented channels from fully closing in the absence of neurotransmitter. Our results are consistent with a model in which the central region of the M2 transmembrane domain is inaccessible in the closed state and moves during channel activation.
authors.affiliation: The Salk Institute for Biological Studies, La Jolla, California 92037, USA.
authors.forename: Sandip
authors.initials: S
authors.lastname: Panicker
authors.forename: Hans
authors.initials: H
authors.lastname: Cruz
authors.forename: Christine
authors.initials: C
authors.lastname: Arrabit
authors.forename: Paul A
authors.initials: PA
authors.lastname: Slesinger
mesh_terms: D019943:Amino Acid Substitution; D000818:Animals; D003545:Cysteine / Q000235:genetics; D018076:DNA, Complementary / Q000235:genetics / Q000378:metabolism; D005020:Ethyl Methanesulfonate / Q000031:analogs & derivatives* / Q000494:pharmacology; D015640:Ion Channel Gating / Q000187:drug effects / Q000502:physiology*; D008024:Ligands; D008698:Mesylates / Q000494:pharmacology; D051379:Mice; D008845:Microinjections; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D009865:Oocytes / Q000378:metabolism; D018408:Patch-Clamp Techniques; D011487:Protein Conformation; D017434:Protein Structure, Tertiary / Q000502:physiology; D011985:Receptors, Serotonin / Q000235:genetics / Q000378:metabolism*; D044406:Receptors, Serotonin, 5-HT3; D017422:Sequence Analysis, DNA; D012701:Serotonin / Q000378:metabolism*; D013329:Structure-Activity Relationship; D014981:Xenopus
chemical_list: D018076:DNA, Complementary; D008024:Ligands; D008698:Mesylates; D011985:Receptors, Serotonin; D044406:Receptors, Serotonin, 5-HT3; C093171:methanethiosulfonate ethylammonium; C109154:(2-(trimethylammonium)ethyl)methanethiosulfonate; D012701:Serotonin; D005020:Ethyl Methanesulfonate; D003545:Cysteine